Advertisement

Topics

Loxo acquires BTK inhibitor program from Redx Pharma

15:40 EDT 1 Aug 2017 | Elsevier Business Intelligence

Loxo Oncology Inc. paid $40mm to acquire Redx Pharma PLC’s preclinical Bruton’s tyrosine kinase (BTK) inhibitor program. ...

Original Article: Loxo acquires BTK inhibitor program from Redx Pharma

NEXT ARTICLE

More From BioPortfolio on "Loxo acquires BTK inhibitor program from Redx Pharma"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...